A ketamine-versus-midazolam imaging contrast helped investigate a mechanistic hypothesis but did not make midazolam an inert baseline.
Three datasets were integrated
The study combined genetic and resting-state imaging information from schizophrenia patients and controls, a double-blind crossover pharmacological imaging study in 28 healthy participants, and regional gene-expression data from postmortem donors. Ketamine and midazolam were the pharmacological comparison.
The authors reported resemblance between a disease-associated genetic effect and the ketamine-versus-midazolam connectivity pattern, interpreting the convergence in terms of excitation-inhibition balance and NMDA-receptor-related dysfunction.
The comparator changes the question
A contrast between two active drugs measures their difference. It does not identify every ketamine effect relative to no drug, nor does it establish that midazolam has no effect on connectivity. The genetic, pharmacological, and donor datasets also came from different people and experimental contexts.
For interpretation, state the comparator explicitly and separate convergent evidence from a proven disease mechanism. The paper does not validate an imaging test for benzodiazepine intoxication or diagnose schizophrenia from a midazolam response. Its value lies in triangulating a biological hypothesis across distinct sources of evidence.
Source paper
Original analysis of the supplied journal article, identified as PMC9935542.
Leave a Reply